Title:
血管内皮成長因子(VEGF)受容体を中和するヒトモノクローナル抗体及びその用途
Document Type and Number:
Japanese Patent JP5086430
Kind Code:
B2
Abstract:
The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.
More Like This:
Inventors:
You, Chinsan
Lee, Wonseop
Sim, san yoru
Park, Mifi
Jung Eun, Kang
Kim, Do Yun
Lee, Jun Chul
Lee Dong Hong
Cho, Tu Hyun
Sol, sam sk
Kwon, Yong Gun
Byeon
Kim, quifa
Yun, Chaeok
Kim, Nam Ju
Jeong Won
Lee Dong-Sup
Park, Yongwoo
La, Cumbe
Chan, Hyun Suk
Hyun Mi
Kim, Sung Woo
Kim, cicada
Ko, Sang Suk
Lee, Wonseop
Sim, san yoru
Park, Mifi
Jung Eun, Kang
Kim, Do Yun
Lee, Jun Chul
Lee Dong Hong
Cho, Tu Hyun
Sol, sam sk
Kwon, Yong Gun
Byeon
Kim, quifa
Yun, Chaeok
Kim, Nam Ju
Jeong Won
Lee Dong-Sup
Park, Yongwoo
La, Cumbe
Chan, Hyun Suk
Hyun Mi
Kim, Sung Woo
Kim, cicada
Ko, Sang Suk
Application Number:
JP2010512050A
Publication Date:
November 28, 2012
Filing Date:
June 26, 2007
Export Citation:
Assignee:
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Pharma Absin Incorporated
Pharma Absin Incorporated
International Classes:
C07K16/28; A61K39/395; A61P9/00; A61P35/00; C12N1/21; C12N5/10; C12N15/09; C12P21/08
Domestic Patent References:
| JP2005526506A |
Attorney, Agent or Firm:
Kenzo Hara International Patent Office